Novo Nordisk's Canadian patent for weight loss drug Ozempic is set to expire in January 2026. Dr. Justin Ezekowitz discusses generic competitors that may come.

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

The Times has amended a headline that incorrectly suggested doctors should monitor patients taking Ozempic injections in ...